Alexandre de la Fuente1, Lorena Alonso-Alconada1, Clotilde Costa1, Juan Cueva1, Tomas Garcia-Caballero1, Rafael Lopez-Lopez1, Miguel Abal2. 1. Translational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC). 2. Translational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC). miguel.abal.posada@sergas.es.
Abstract
BACKGROUND: Remodeling targeted tissues for reception of tumor cells metastasizing from primary lesions is a consequence of communication between the tumor and the environment that governs metastasis. This study describes a novel approach that aims to disrupt the process of metastasis by interfering with this intense dialogue. METHODS: Proteomics and adhesion assays identified exosomes purified from the ascitic fluid of ovarian cancer patients (n = 9) as intermediaries of tumor cell attachment. A novel tumor cell capture device was fabricated by embedding exosomes onto a 3D scaffold (metastatic trap [M-Trap]). Murine models of ovarian metastasis (n = 3 to 34 mice per group) were used to demonstrate the efficacy of M-Trap to capture metastatic cells disseminating in the peritoneal cavity. Kaplan-Meier survival curves were used to estimate cumulative survival probabilities. All statistical tests were two-sided. RESULTS: The exosome-based M-Trap device promoted tumor cell adhesion with a nonpharmacological mode of action. M-Trap served as a preferential site for metastasis formation and completely remodeled the pattern of peritoneal metastasis in clinically relevant models of ovarian cancer. Most importantly, M-Trap demonstrated a statistically significant benefit in survival outcomes, with mean survival increasing from 117.5 to 198.8 days in the presence of M-Trap; removal of the device upon tumor cell capture further improved survival to a mean of 309.4 days (P < .001). CONCLUSIONS: A potent artificial premetastatic niche based on exosomes is an effective approach to impair the crosstalk between metastatic cells and their environment. In the clinical setting, the capacity to modulate the pattern of dissemination represents an opportunity to control the process of metastasis. In summary, M-Trap transforms a systemic, fatal disease into a focalized disease where proven therapeutic approaches such as surgery can extend survival.
BACKGROUND: Remodeling targeted tissues for reception of tumor cells metastasizing from primary lesions is a consequence of communication between the tumor and the environment that governs metastasis. This study describes a novel approach that aims to disrupt the process of metastasis by interfering with this intense dialogue. METHODS: Proteomics and adhesion assays identified exosomes purified from the ascitic fluid of ovarian cancerpatients (n = 9) as intermediaries of tumor cell attachment. A novel tumor cell capture device was fabricated by embedding exosomes onto a 3D scaffold (metastatic trap [M-Trap]). Murine models of ovarian metastasis (n = 3 to 34 mice per group) were used to demonstrate the efficacy of M-Trap to capture metastatic cells disseminating in the peritoneal cavity. Kaplan-Meier survival curves were used to estimate cumulative survival probabilities. All statistical tests were two-sided. RESULTS: The exosome-based M-Trap device promoted tumor cell adhesion with a nonpharmacological mode of action. M-Trap served as a preferential site for metastasis formation and completely remodeled the pattern of peritoneal metastasis in clinically relevant models of ovarian cancer. Most importantly, M-Trap demonstrated a statistically significant benefit in survival outcomes, with mean survival increasing from 117.5 to 198.8 days in the presence of M-Trap; removal of the device upon tumor cell capture further improved survival to a mean of 309.4 days (P < .001). CONCLUSIONS: A potent artificial premetastatic niche based on exosomes is an effective approach to impair the crosstalk between metastatic cells and their environment. In the clinical setting, the capacity to modulate the pattern of dissemination represents an opportunity to control the process of metastasis. In summary, M-Trap transforms a systemic, fatal disease into a focalized disease where proven therapeutic approaches such as surgery can extend survival.
Authors: Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine Journal: Semin Oncol Date: 2011-08 Impact factor: 4.929
Authors: Jonathan P Sleeman; Gerhard Christofori; Riccardo Fodde; John G Collard; Geert Berx; Charles Decraene; Curzio Rüegg Journal: Semin Cancer Biol Date: 2012-02-21 Impact factor: 15.707
Authors: Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden Journal: Nat Med Date: 2012-06 Impact factor: 53.440
Authors: Kathryn M Burleson; Rachael C Casey; Keith M Skubitz; Stephan E Pambuccian; Theodore R Oegema; Amy P N Skubitz Journal: Gynecol Oncol Date: 2004-04 Impact factor: 5.482
Authors: Mara P Steinkamp; Kimberly Kanigel Winner; Suzy Davies; Carolyn Muller; Yong Zhang; Robert M Hoffman; Abbas Shirinifard; Melanie Moses; Yi Jiang; Bridget S Wilson Journal: Front Oncol Date: 2013-05-17 Impact factor: 6.244
Authors: Oystein Helland; Mihaela Popa; Olav K Vintermyr; Anders Molven; Bjørn Tore Gjertsen; Line Bjørge; Emmet McCormack Journal: PLoS One Date: 2014-03-04 Impact factor: 3.240
Authors: Grace G Bushnell; Tejaswini P Hardas; Rachel M Hartfield; Yining Zhang; Robert S Oakes; Scott Ronquist; Haiming Chen; Indika Rajapakse; Max S Wicha; Jacqueline S Jeruss; Lonnie D Shea Journal: Cancer Res Date: 2019-02-26 Impact factor: 12.701
Authors: Aaron H Morris; Sophia M Orbach; Grace G Bushnell; Robert S Oakes; Jacqueline S Jeruss; Lonnie D Shea Journal: Cancer Res Date: 2020-05-14 Impact factor: 12.701
Authors: Grace G Bushnell; Xiaowei Hong; Rachel M Hartfield; Yining Zhang; Robert S Oakes; Shreyas S Rao; Jacqueline S Jeruss; Jan P Stegemann; Cheri X Deng; Lonnie D Shea Journal: Ann Biomed Eng Date: 2019-09-23 Impact factor: 3.934
Authors: Grace G Bushnell; Shreyas S Rao; Rachel M Hartfield; Yining Zhang; Robert S Oakes; Jacqueline S Jeruss; Lonnie D Shea Journal: Biotechnol Bioeng Date: 2019-10-03 Impact factor: 4.530
Authors: P Zarzosa; N Navarro; I Giralt; C Molist; A Almazán-Moga; I Vidal; A Soriano; M F Segura; R Hladun; A Villanueva; S Gallego; J Roma Journal: Clin Transl Oncol Date: 2016-10-07 Impact factor: 3.405
Authors: Grace G Bushnell; Sophia M Orbach; Jeffrey A Ma; Howard C Crawford; Max S Wicha; Jacqueline S Jeruss; Lonnie D Shea Journal: Biomaterials Date: 2020-12-23 Impact factor: 12.479